Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 43Lymphoma, Non-Hodgkin 24Lymphoma, Follicular 17Lymphoma 14Recurrence 11Lymphoma, Large B-Cell, Diffuse 11Lymphoma, B-Cell 9Neoplasms 5Lymphoma, B-Cell, Marginal Zone 4Melanoma 3Leukemia 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Leukemia, B-Cell 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Urinary Bladder Neoplasms 1Tumor Lysis Syndrome 1Solid Cancers 1Prostatic Neoplasms 1Part1: Advanced B-cell Malignancies 1Ovarian Neoplasms 1Oncology Patients Receiving Chemotherapy 1Neoplasm Metastasis 1Mesothelioma 1Mature B-cell Malignancies 1

Interventions

ibrutinib 6pirtobrutinib 2blinatumomab 2tozasertib 1ofatumumab 1oblimersen 1obinutuzumab 1mocetinostat 1lucatumumab 1forodesine 1fenebrutinib 1enzastaurin 1Mitoxantrone 1Epoetin Alfa 1Bendamustine Hydrochloride 1Antineoplastic Agents 1ARQ531 12-(2-oxo-2-((3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy)aminoethyl)phosphonic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester sodium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Lymphoid × obinutuzumab × Clear all
NCT01680991 2016-04-25

A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Hoffmann-La Roche

Phase 1 Completed
48 enrolled 27 charts
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoid, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡